reason report
solid guidanc revis posit
bottom line kick earn season
ep beat come compar consensu
revenu also beat consensu
importantli tax reform adjust ep guidanc
compar previou guidanc day
repres upsid compar expect
expect posit catalyst consensu move
post investor day dec jan time-fram
expect sell analyst revis ep
upward tax reform consolid compar
consensu view point modest uptick util
quarter see report solid posit come
pleas refer page import disclosur price chart analyst certif
ana gupt ph certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
primari valuat methodolog base rel price-to-earnings rel price-to-earnings track function
compani histori manag group averag assess potenti price-to-earnings expans
next month base forward forecast contempl underli fundament implic
healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect greater potenti
multipl expans dcf valuat point significantli upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans except low ratio
and/or high free cash flow yield point potenti greater multipl expans
rate outperform price target contempl price-to-earnings bull-cas cash
ep
risk valuat
non-profit bcb plan insur price irrat commerci market rapidli acceler medic cost
medic cost trend come higher anticip potenti double-dip recess provid re-up
intens servic deliveri cobra acceler uptak member util care advanc lay-off
employ exit rapidli sponsorship health benefit combat medic cost inflat catalyz
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus substanti underwrit margin
long-term state base health insur exchang advers select reduc sustain earn power
employ dump employe health insur exchang signific margin compress also
potenti downsid membership top line also present long-term risk
risk relat collect industri fee medicar medicaid premium
polit shock lead singl payer
compani specif risk downsid risk price target includ acquisit asset arena
yield adequ return capit
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark
market capit less billion
capit billion
health index issuer
health index issuer market
inform includ limit price quot statist obtain sourc
believ reliabl repres accur complet reli
upon inform subject chang without notic provid inform purpos
regard offer sell solicit offer buy product
inform relat firm offic director employe proprietari account affili may
posit long short secur refer report and/or relat secur
time time may increas decreas posit express view contrari contain
report firm salespeopl trader profession may provid oral written market
commentari trade strategi contrari opinion express report firm proprietari
account may make invest decis inconsist opinion express report
past perform secur guarante predict futur perform transact strategi
describ herein may suitabl investor addit inform avail upon request
contact editori depart one feder street floor boston
like firm employe analyst receiv compens impact among factor overal firm
profit includ revenu among busi unit institut equiti invest
bank analyst howev compens specif invest bank servic transact
contribut firm invest bank activ
medacorp network healthcar profession attorney physician key opinion leader
specialist access leerink provid inform use analyst prepar research
leerink partner llc make market inc
leerink partner llc will sell buy client common stock inc
princip basi
leerink place outperform rate octob
member finra/sipc leerink partner llc right reserv document may reproduc
circul without written author
director equiti research
associ director research
director research
mid- small-cap biotechnolog
